Mahamaya Lifesciences Ltd
- Market Cap ₹ 267 Cr.
- Current Price ₹
- High / Low ₹ /
- Stock P/E 48.9
- Book Value ₹
- Dividend Yield %
- ROCE 21.4 %
- ROE 24.3 %
- Face Value ₹ 10.0
Pros
Cons
- Debtor days have increased from 44.7 to 64.0 days.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | |
|---|---|---|
| 137 | 162 | |
| 128 | 148 | |
| Operating Profit | 9 | 13 |
| OPM % | 7% | 8% |
| 0 | 1 | |
| Interest | 3 | 6 |
| Depreciation | 1 | 1 |
| Profit before tax | 5 | 8 |
| Tax % | 28% | 27% |
| 4 | 5 | |
| EPS in Rs | ||
| Dividend Payout % | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 18% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 47% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 24% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Equity Capital | 1 | 1 |
| Reserves | 18 | 24 |
| 24 | 54 | |
| 34 | 33 | |
| Total Liabilities | 78 | 112 |
| 21 | 21 | |
| CWIP | 2 | 3 |
| Investments | 0 | 0 |
| 55 | 88 | |
| Total Assets | 78 | 112 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Net Cash Flow |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2023 | Mar 2024 | |
|---|---|---|
| Debtor Days | 25 | 64 |
| Inventory Days | 109 | 137 |
| Days Payable | 90 | 65 |
| Cash Conversion Cycle | 45 | 136 |
| Working Capital Days | 14 | 20 |
| ROCE % | 21% |
Documents
Annual reports
No data available.